New Frontiers in Medulloblastoma Treatment
What is medulloblastoma, and where does it develop in the brain?
Medulloblastoma is a fast-growing, malignant brain tumour that originates in the cerebellum. At the back of the brain, the cerebellum masterfully controls balance, coordination, and fine motor skills. Medulloblastomas arise from undeveloped nerve cells and primarily affect children, although they can also occur in adults. These tumours belong to a group known as primitive neuroectodermal tumours (PNETs) and often spread through the cerebrospinal fluid to other parts of the brain and spinal cord.
 |
| Medulloblastoma Patient |
Why are medulloblastomas frequent in children?
Medulloblastomas are more common in children because of the unique characteristics of the developing brain. During early childhood, the brain undergoes rapid growth and cell division, especially in the cerebellum, where medulloblastoma typically originates. This period of intense development involves immature nerve cells, known as neuroectodermal cells, which are more vulnerable to genetic changes or abnormal growth patterns.
Unlike adults, children have a significant proportion of these undeveloped cells, increasing the risk of tumour formation. Additionally, certain inherited genetic conditions, such as Gorlin syndrome or Li-Fraumeni syndrome, further raise the likelihood of medulloblastoma in young individuals. The immature brain may also lack some natural regulatory mechanisms that control cell growth, making it more susceptible to tumour development. Biological and genetic factors underlying these mechanisms explain why medulloblastomas occur more frequently in children than adults.
Who is most commonly affected by medulloblastoma – children or adults?
Medulloblastoma most commonly affects children, particularly those between the ages of 3 and 8. It is the most frequent malignant brain tumour in paediatric patients. While medulloblastoma can also occur in adults, it is relatively rare. Medulloblastoma typically appears in adults between 20 and 40, though its incidence is significantly lower than in children. Children are more vulnerable due to rapid brain development and the presence of immature nerve cells, which are more likely to undergo abnormal changes leading to tumour growth.
What are the early signs and symptoms of medulloblastoma?
Early signs and symptoms of medulloblastoma often arise due to increased pressure inside the skull and the tumour's location in the cerebellum. These include:
- Headaches, especially in the morning or worsening over time
- Nausea and vomiting, often unrelated to food
- Balance problems and unsteady walking (ataxia)
- Difficulty with coordination or fine motor tasks
- Dizziness or a sense of spinning (vertigo)
- Vision problems, such as double vision or uncontrolled eye movements
- Behavioural changes, irritability, or lethargy in young children
- Enlarged head size or bulging fontanelle in infants
These symptoms require prompt medical evaluation, especially when they persist or worsen over days or weeks.
How is medulloblastoma diagnosed (imaging, biopsy, spinal fluid test)?
Doctors diagnose medulloblastoma through fusion imaging, laboratory tests, and tissue analysis. The key diagnostic steps include:
- Magnetic Resonance Imaging (MRI): MRI of the brain and spine is the primary tool. Imaging scans provide clear visuals of tumour size, location, and development, especially in the cerebellum and spinal cord. Contrast-enhanced MRI helps in better visualisation.
- Computed Tomography (CT) Scan: Sometimes used in emergencies, especially to detect signs of raised intracranial pressure or hydrocephalus.
- Surgical Biopsy or Tumour Resection: Surgeons remove a portion or the entire tumour for histopathological examination. This process confirms the diagnosis and helps classify the tumour type.
- Lumbar Puncture (Spinal Tap): Doctors collect cerebrospinal fluid (CSF) to check for cancer cells. This test helps detect whether the tumour has spread through the CSF pathways.
- Molecular and Genetic Testing: Analysing tumour tissue for genetic mutations or molecular subgroups (e.g., WNT, SHH, Group 3, Group 4) helps guide treatment and predict outcomes.
Accurate diagnosis ensures proper staging and helps in planning effective treatment.
 |
| Happy patient after Medulloblastoma treatment |
What are the main treatment options (surgery, radiation, chemotherapy?
The main treatment options for medulloblastoma involve a combination of surgery, radiation, and chemotherapy. The approach depends on the patient's age, tumour type, and extent of spread.
Surgery:
- Surgeons aim to remove as much of the tumour as safely as possible, and this stage is often the first step. Complete or near-complete resection improves outcomes and reduces tumour pressure on the brain.
Radiation Therapy:
- Craniospinal irradiation, targeting the brain and spinal cord, is standard for children over age three and adults. It targets remaining cancer cells and prevents spread through cerebrospinal fluid pathways.
- In younger children (under 3 years), doctors usually delay or avoid radiation due to potential harm to the developing brain.
Chemotherapy:
- Chemotherapy helps destroy cancer cells that may remain after surgery and radiation. It is vital in young children and those with high-risk or metastatic disease. Surgeons prefer chemotherapy before or after radiation and sometimes as part of clinical trials.
Targeted Therapy and Clinical Trials:
- Some cases may benefit from targeted therapies based on genetic testing. Clinical trials often offer advanced treatment options, especially for relapsed or high-risk cases.
This multi-modal treatment plan improves survival and reduces the risk of recurrence, though long-term monitoring and rehabilitation are often needed.
 |
| Medulloblastoma-brain tumour |
What is the Recovery time after surgery, radiation, and chemotherapy?
Recovery time after treatment for medulloblastoma varies based on the patient’s age, tumour size, treatment intensity, and overall health. Below is a general outline:
After Surgery:
- A hospital stay usually lasts 5 to 10 days.
- Initial recovery, including wound healing and regaining strength, may take 2 to 4 weeks.
- Some children need rehabilitation for balance, coordination, or speech, which can extend over months.
After Radiation Therapy:
- Side effects like fatigue, nausea, or skin changes may last a few weeks after treatment ends.
- Brain and spinal radiation effects on learning and growth may appear months or years later.
After Chemotherapy:
- Recovery from each cycle takes a few days to 2 weeks, depending on the drugs used.
- The recovery of the immune system and body strength may take several months after completing all cycles.
- Long-term effects (hearing, fertility, organ function) may require continuous monitoring.
Overall, complete physical recovery may take 6 to 12 months, while emotional, cognitive, and developmental recovery may need years of support and follow-up.
What are the possible long-term effects or complications after treatment?
Long-term effects or complications after medulloblastoma treatment can vary based on age, treatment intensity, and tumour location. Common issues include:
Cognitive and Learning Difficulties:
- Radiation and chemotherapy may affect memory, attention, processing speed, and school performance, especially in young children.
Hearing Loss:
- Certain chemotherapy drugs (like cisplatin) may damage hearing, requiring hearing aids or speech therapy.
Endocrine Problems:
- Radiation near the brain can harm the hypothalamus or pituitary gland, causing growth delays, thyroid issues, or puberty disorders.
Balance and Coordination Problems:
- Surgery and damage to the cerebellum may result in lasting issues with walking, coordination, or fine motor skills.
Emotional and Behavioural Challenges:
- Children may face anxiety, depression, mood swings, or social difficulties due to brain changes or the stress of treatment.
Second Cancers:
- Radiation and chemotherapy can slightly raise the risk of developing secondary tumours years later.
Spinal and Bone Growth Issues:
- Radiation in growing children may affect spine development or cause scoliosis. Tumour growth can cause hydrocephalus by obstructing the normal circulation of cerebrospinal fluid.
Regular follow-up, including physical, psychological, and educational support, helps manage these long-term effects and improves the child’s quality of life.
What is the current prognosis and survival rate for medulloblastoma patients?
The prognosis for medulloblastoma has improved significantly due to advances in surgery, radiation, and chemotherapy. Survival rates vary depending on age, tumour subtype, and extent of spread at diagnosis.
Standard-risk patients (no spread, near-total tumour removal):
- The 5-year survival rate is about 70% to 85%.
High-risk patients (spread to the spine or incomplete resection):
- The 5-year survival rate ranges from 50% to 70%.
Favourable molecular subtypes (e.g. WNT group):
- These have the best outcomes, with survival rates often exceeding 90%.
Less favourable subtypes (e.g. Group 3 with metastasis):
- These have poorer outcomes, with survival rates below 50% in some cases.
Patient outcomes depend on timely diagnosis, the tumour's biological characteristics, and access to thorough treatment and rehabilitation. Lifelong follow-up helps manage late effects and detect recurrence early.
What are the most recent techniques of medulloblastoma treatment?
Researchers are revolutionising medulloblastoma treatment with innovative strategies that enhance patient outcomes and minimise long-term side effects. These developments focus on precision medicine, immunotherapy, and advanced radiation techniques.
1. Molecularly Targeted Therapies
- Researchers at St. Jude Children's Research Hospital have identified a compound that selectively targets the EP300/CBP proteins in Group 3 medulloblastoma, enhancing anti-tumour activity and reducing cancer cell growth.
- A breakthrough discovery involving the KCNB2 gene suggests that targeting this gene could enhance current treatments, addressing tumour-propagating cells that often survive standard therapies.
2. Immunotherapy Approaches
- The University of Florida is testing a combination of precision adaptive T-cell therapy and immune checkpoint blockade using PD-1 inhibitors. This approach aims to boost the immune system's ability to fight medulloblastoma cells.
3. Differentiation Therapy
- Fox Chase Cancer Centre researchers have explored using thyroid hormone (T3) to induce differentiation in medulloblastoma tumour cells. This strategy causes cancer cells to mature into less aggressive forms, slowing tumour growth.
4. Advanced Radiation Techniques
- Proton and intensity-modulated radiation therapy (IMRT) have improved treatment precision, reducing radiation exposure to adjacent tissues. These techniques are particularly beneficial for young children to minimise long-term side effects.
5. Novel Diagnostic Tools
- Canadian researchers have developed a new test that effectively identifies aggressive medulloblastoma, potentially sparing young patients from unnecessary treatments and their harmful long-term side effects.
6. Emerging Clinical Trials
The Medulloblastoma Initiative has opened two new FDA-approved clinical trials targeting relapsed Group 4 medulloblastoma, representing the first human trials of their kind. Emerging treatments for medulloblastoma are revolutionising patient care, offering more personalised and less invasive options that boost survival rates and quality of life.
Conclusion:
Medulloblastoma, though a serious paediatric brain tumour, now faces a hopeful future due to modern diagnostics and advanced therapies. With precision medicine, targeted treatments, and improved surgical and radiation techniques, survival rates continue to rise. Ongoing research into molecular subtypes and immunotherapy further refines care. Early diagnosis, multidisciplinary treatment, and lifelong support are key. Today, medulloblastoma care reflects a growing focus on curing the disease and preserving the quality of life for survivors.